Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 2/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.37 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1953417 | 0.98 | TBXAS1 (0.50) | CYP2B6TBXAS1ACHEALDH1A1CYP11B1 | |
| SCHEMBL8699805 | 0.82 | ACHE (0.59) | CYP2B6TBXAS1ACHECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL28306929 | 0.80 | ACHE (0.57) | CYP2B6TBXAS1ACHECYP1A2CYP3A4 | |
| SCHEMBL11008025 | 0.80 | TBXAS1 (0.45) | CYP2B6TBXAS1ACHEALDH1A1CYP11B1 | |
| SCHEMBL11011577 | 0.79 | ACHE (0.60) | CYP2B6TBXAS1ACHECYP1A2CYP3A4 | |
| SCHEMBL7739959 | 0.79 | ACHE (0.64) | CYP2B6TBXAS1ACHEQPCT | |
| SCHEMBL19596990 | 0.79 | ACHE (0.64) | CYP2B6TBXAS1ACHEQPCT | |
| SCHEMBL2143890 | 0.77 | TBXAS1 (0.67) | CYP2B6TBXAS1ALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL9030088 | 0.75 | LMNA (0.52) | CYP2B6TBXAS1ACHE | |
| SCHEMBL27491539 | 0.73 | MEN1 (0.45) | ALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1935887-B1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| CN-1285588-C | Farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1632483-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1362039-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | AVENTIS PHARMACEUTICAL INC. (US) | 2004-11-04 | — | — | US | disclosed |
| EP-1362039-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| CN-1352642-A | Farnesyl protein transferase inhibitors | SCHERING CORP (US) | 2002-06-05 | — | — | CN | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| US-4528195-A | Imidazole derivatives and salts thereof, their synthesis and intermediates and pharmaceutical formulations | THOROGOOD PETER B (GB) | 1985-07-09 | — | — | US | disclosed |
| EP-0003560-B1 | IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| US-4416895-A | ANTICOAGULANTS, ANTISHOCK AGENTS | BURROUGHS WELLCOME CO. (US) | 1983-11-22 | — | — | US | disclosed |
| EP-0003560-A2 | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations | THE WELLCOME FOUNDATION LIMITED (GB) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220173-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor | DRD3, DRD2, DRD1 | CYP2B6 1722/4885TBXAS1 2727/4885ACHE 2925/4885 |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | DRD3, DRD2, HTR3C | CYP2B6 1671/4885TBXAS1 2810/4885ACHE 2795/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | CYP2B6 1467/4885TBXAS1 2616/4885ACHE 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.